Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (09/28/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Risk-Based Treatment Assignment

Added Winick et al. as reference 45.

Revised text to state that BCR-ABL1–like acute lymphoblastic leukemia (ALL) occurs in 10% to 20% of pediatric ALL patients, increasing in frequency with age, and has been associated with a poor prognosis and with IKZF1 deletion or mutation (cited Reshmi et al. as reference 213).

Added Schmäh et al. as reference 221.

Postinduction Treatment for Childhood ALL

Added text about a follow-up study that explored mercaptopurine ingestion habits, red cell thioguanine nucleotide levels, adherence, and relapse risk (cited Landier et al. as reference 70 and level of evidence 2Diii).

Treatment of Relapsed Childhood ALL

Added text about the results of a phase I trial of 45 children and young adults with relapsed/refractory CD19-positive B-cell ALL who received 4-1BB–based lentiviral vector expanded CAR T cells (cited Gardner et al. as reference 134).

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Treatment of Relapsed Childhood ALL

Next section >
About This PDQ Summary